Chief Executive Albert Bourla told analysts he is hopeful about finding a solution in response to President Trump’s demands.

U.S. stocks closed rallied on Friday, with the Nasdaq Composite (COMP:IND) securing another back-to-back record, even as ...

Pfizer said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting ...

On the company’s Q2 earning call, Pfizer (PFE) noted that the company’s guidance “absorbs the impact of the currently imposed ...

Pfizer delivered a strong Q2 earnings beat, raising FY2025 guidance and demonstrating effective cost-cutting. Learn why PFE ...

As investors and industry watchers juggle the twin possibilities of pharmaceutical import tariffs and potential drug pricing ...

Pfizer's oncology pipeline looks promising. The company's newer approvals could make significant progress. And its efforts to ...

Pfizer beats Q2 2025 estimates, raises EPS guidance, boasts a 7%+ dividend yield, yet faces patent and pricing risks. See why ...

Albert Bourla confirmed that he called President Donald Trump after receiving a letter asking Pfizer and a clutch of other ...

Pfizer said the new forecast includes a one-time charge of 20 cents per share related to its recent licensing deal with China ...

Pharmaceuticals account for the bulk of Irish exports to the US and any change, or even uncertainty, on tariffs poses major ...

STORY: Pfizer raised its full-year profit forecast on Tuesday (August 5).It said it expects to benefit from cost-cutting and ...